KLOW Peptide BlendGLOW plus an anti-inflammatory arm — a branded four-peptide stack, not a molecule

Four real peptides, one brand name, zero blend trials.

KLOW is essentially GLOW with a fourth peptide bolted on: BPC-157, GHK-Cu, and TB-500 (the GLOW trio) plus KPV, an α-MSH-derived anti-inflammatory tripeptide that adds an "upstream NF-κB" arm to the repair logic. The honest framing is the same as GLOW, only more so: it's a branded commercial blend, not a molecule — no single CAS, formula, or PubChem ID — and the genuine human evidence belongs to individual components in routes that aren't the injectable blend (topical GHK-Cu skin studies, topical/ophthalmic full-Tβ4 wound trials). KPV is well-characterized preclinically but has no published human trial. There is no controlled trial of the KLOW blend, BPC-157 and TB-500 are unapproved and anti-doping-restricted, and a common vendor format fixes the ratio at 80 mg (50 GHK-Cu / 10 KPV / 10 BPC-157 / 10 TB-500).

Four peptides, four jobs, one repair hypothesis.

KLOW's logic divides the repair problem into four roles: KPV calms inflammation upstream (NF-κB suppression after PepT1 uptake), GHK-Cu rebuilds the matrix (collagen/elastin/GAG, copper-dependent enzymes), thymosin-β4/TB-500 mobilizes repair cells (actin-based migration, angiogenesis), and BPC-157 adds cytoprotection and vascular hypotheses. KPV is what distinguishes KLOW from GLOW — an anti-inflammatory arm with the activity of α-MSH but without its pigmentation/appetite effects. The honest grading stays component-level: GHK-Cu has some human skin support, KPV and the rest are preclinical, and the blend-level synergy is an unproven hypothesis. The angiogenesis node is explicitly a double-edged sword in malignancy.

No validated dose — only blend-equivalent arithmetic.

KLOW has no FDA-approved indication, label, dose, route, manufacturing standard, or approved composition. Because it's a fixed-ratio blend rather than four separate vials, the calculator below works in blend-equivalent mg — you reconstitute the whole vial, then a given draw delivers all four peptides in their fixed proportion. The common vendor format is 80 mg total (50 GHK-Cu / 10 KPV / 10 BPC-157 / 10 TB-500), i.e. 62.5% / 12.5% / 12.5% / 12.5%. The calculator validates concentration, draw volume, and per-component breakdown — it does not recommend a dose. Component peptides have been named in FDA compounding-risk discussions and are under PCAC review in 2026, so this page is date-stamped and is not prescribing guidance.

A blend that's already four peptides deep.

KLOW is itself a four-peptide combination, so the meaningful "stacking" question is mostly about what people add on top — and the honest answer is usually "nothing that's been studied." Pairing KLOW with GLOW double-counts BPC-157/GHK-Cu/TB-500 exposure; pairing it with NAD+ or GLP-1 therapy is marketing positioning without synergy data; and using it around procedures runs into the same supervision requirements as any injectable. The hard constraint mirrors GLOW's, with KPV's immune modulation adding an autoimmune caution: avoid in active malignancy, unexplained masses, proliferative retinopathy, pregnancy/breastfeeding, tested athletics, and uncontrolled infection, because the blend's repair/angiogenesis/inflammation pathways are not safety-validated.

Mostly unknown — four times over.

KLOW's safety story is GLOW's, plus a fourth peptide: there is no long-term systemic safety database for the injectable blend, no human PK, and no controlled trial. The component pieces are reassuring in their studied forms (topical GHK-Cu, full-Tβ4 wound trials, KPV's clean preclinical colitis safety, BPC-157's benign animal profile), but none of that validates chronic injected four-peptide use. The concrete hazards are practical and shared with every gray-market blend: product quality (identity, purity, endotoxin, sterility, dose consistency), injection-site reactions, and using peptides in place of real medical care. The theoretical concern anchoring the contraindications is the angiogenesis double-edged sword — thymosin-β4's link to tumor angiogenesis and metastasis makes active malignancy a firm avoid.

Practical safety framework

Contraindications & cautions

Four components' worth of evidence — none of it the blend.

KLOW's evidence pattern is the four-peptide version of GLOW's: real human evidence exists in this space, but none of it is for the injectable blend. GHK-Cu has human topical/cosmetic skin data; thymosin-β4 has Phase-2 topical wound trials (venous ulcer) and ophthalmic dry-eye trials — but as full-length Tβ4, not the SC fragment; KPV has robust preclinical colitis efficacy with clean safety but no published human trial; and BPC-157's human evidence is limited to a small uncontrolled knee-pain injection report and an n=2 IV pilot. There is no controlled human trial of the KLOW blend at all. So KLOW is biologically plausible and component-supported, but its own evidence is absent, and the supporting studies use different molecules and different routes.

KLOW vs GLOW and its components.

The clearest way to place KLOW is against GLOW and the individual peptides. KLOW is GLOW plus KPV — the same three-peptide repair core with an added α-MSH-derived anti-inflammatory arm, positioned more toward "recovery and inflammation" than pure aesthetics. As with GLOW, the blend's evidence is weaker than the sum of its parts: each component has a clearer, route-specific identity and evidence base than the combination. The throughline holds — the components are real and partly evidence-backed, but the injectable "KLOW" blend is a marketing construct without its own trial, and adding a fourth peptide adds rationale and risk without adding combination data.

Related peptides.

The same blend, three depths.

Source register.

Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. The pattern is the four-component version of GLOW's: the Grade-B sources are full-length thymosin-β4 human studies (venous ulcer, dry eye) and GHK-Cu human skin data — never the injectable blend or the TB-500 fragment; KPV and BPC-157 mechanistic/preclinical work is Grade C/P; BPC-157's human entries are an n=16 uncontrolled report (Grade D); and the blend-defining and regulatory sources are Grade D commercial/regulatory records. There is no Grade-A or direct-combination source. The grade distribution makes the page's core point visible: KLOW's genuine evidence belongs to its components in routes that aren't the marketed injectable blend.

More Repair / Immune peptides & tools.